These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 31332257)
1. A set of molecular markers predicts chemosensitivity to Mitomycin-C following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis. Shannon NB; Tan JW; Tan HL; Wang W; Chen Y; Lim HJ; Tan QX; Hendrikson J; Ng WH; Loo LY; Skanthakumar T; Wasudevan SD; Kon OL; Lim TKH; Tan GHC; Chia CS; Soo KC; Ong CJ; Teo MCC Sci Rep; 2019 Jul; 9(1):10572. PubMed ID: 31332257 [TBL] [Abstract][Full Text] [Related]
2. Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases. Hulshof EC; Lurvink RJ; Caserta N; de Hingh IHJT; van Wezel T; Böhringer S; Swen JJ; Gelderblom H; Guchelaar HJ; Deenen MJ Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1925-1931. PubMed ID: 32354538 [TBL] [Abstract][Full Text] [Related]
3. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720 [TBL] [Abstract][Full Text] [Related]
4. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center. Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814 [TBL] [Abstract][Full Text] [Related]
5. Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent. Sipok A; Sardi A; Nieroda C; King MC; Sittig M; Gushchin V Int J Surg Oncol; 2018; 2018():1920276. PubMed ID: 30643644 [TBL] [Abstract][Full Text] [Related]
6. Delta peritoneal cancer index (ΔPCI): A new dynamic prognostic parameter for survival in patients with colorectal peritoneal metastases. Hentzen JEKR; van der Plas WY; Kuipers H; Ramcharan S; Been LB; Hoogwater FJH; van Ginkel RJ; van Dam GM; Hemmer PHJ; Kruijff S Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):590-599. PubMed ID: 31806520 [TBL] [Abstract][Full Text] [Related]
7. Peritoneal carcinomatosis in colorectal cancer: Defining predictive factors for successful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A pilot study. Mahmoud AM; Ismail YM; Hussien A; Debaky Y; Ahmed IS; Mikhael HSW; Moneer M J Egypt Natl Canc Inst; 2018 Dec; 30(4):143-150. PubMed ID: 30472198 [TBL] [Abstract][Full Text] [Related]
8. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study. Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819 [TBL] [Abstract][Full Text] [Related]
9. Effect of oxaliplatin-based chemotherapy on chemosensitivity in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: proof-of-concept study. Prabhu A; Brandl A; Wakama S; Sako S; Ishibashi H; Mizumoto A; Takao N; Ichinose M; Motoi S; Liu Y; Yonemura Y BJS Open; 2021 Mar; 5(2):. PubMed ID: 33839755 [TBL] [Abstract][Full Text] [Related]
10. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort. Frøysnes IS; Larsen SG; Spasojevic M; Dueland S; Flatmark K J Surg Oncol; 2016 Aug; 114(2):222-7. PubMed ID: 27173150 [TBL] [Abstract][Full Text] [Related]
11. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer. Wisselink DD; Braakhuis LLF; Gallo G; van Grevenstein WMU; van Dieren S; Kok NFM; de Reuver PR; Tanis PJ; de Hingh IHJT Crit Rev Oncol Hematol; 2019 Oct; 142():119-129. PubMed ID: 31400583 [TBL] [Abstract][Full Text] [Related]
12. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116 [TBL] [Abstract][Full Text] [Related]
13. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis. Lin EK; Hsieh MC; Chen CH; Lu YJ; Wu SY Medicine (Baltimore); 2016 Dec; 95(52):e5522. PubMed ID: 28033247 [TBL] [Abstract][Full Text] [Related]
14. Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival. Kwakman R; de Cuba EM; de Winter JP; de Hingh IH; Delis-van Diemen PM; Tijssen M; Rooimans MA; Krijgsman O; Carvalho B; Peters GJ; Bonjer HJ; Meijer GA; Te Velde EA Br J Cancer; 2015 Mar; 112(5):851-6. PubMed ID: 25668003 [TBL] [Abstract][Full Text] [Related]
15. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304 [TBL] [Abstract][Full Text] [Related]
16. Prolonged perioperative thoracic epidural analgesia may improve survival after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A comparative study. Lorimier G; Seegers V; Coudert M; Dupoiron D; Thibaudeau E; Pouplin L; Lebrec N; Dubois PY; Dumont F; Guérin-Meyer V; Capitain O; Campone M; Wernert R Eur J Surg Oncol; 2018 Nov; 44(11):1824-1831. PubMed ID: 30213715 [TBL] [Abstract][Full Text] [Related]
17. Hepatectomy for metachronous colorectal liver metastases following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases: a report of three cases. Ito K; Takemura N; Inagaki F; Mihara F; Kurokawa T; Gohda Y; Kiyomatsu T; Yano H; Kokudo N World J Surg Oncol; 2019 Jun; 17(1):99. PubMed ID: 31196097 [TBL] [Abstract][Full Text] [Related]
18. Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial. Glockzin G; Zeman F; Croner RS; Königsrainer A; Pelz J; Ströhlein MA; Rau B; Arnold D; Koller M; Schlitt HJ; Piso P Clin Colorectal Cancer; 2018 Dec; 17(4):285-296. PubMed ID: 30131226 [TBL] [Abstract][Full Text] [Related]
19. Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience. Narasimhan V; Britto M; Pham T; Warrier S; Naik A; Lynch AC; Michael M; Tie J; Ramsay R; Heriot A Dis Colon Rectum; 2019 Oct; 62(10):1195-1203. PubMed ID: 31490828 [TBL] [Abstract][Full Text] [Related]